Dickkopf-1 as a potential therapeutic target in Paget's disease of bone

Hdl Handle:
http://hdl.handle.net/10034/197704
Title:
Dickkopf-1 as a potential therapeutic target in Paget's disease of bone
Authors:
McCarthy, Helen S.; Marshall, Michael J.
Abstract:
This article discusses Dickkopf-1 (DKK-1), which is a soluble inhibitor of Wnt signalling and its excessive expression contributes to bone loss in rheumatoid arthritis and multiple myeloma. New therapeutics have been developed for treatment of these conditions that target DKK-1 expression. DKK-1 is elevated in serum of patients with Paget's disease of the bone (PDB) and evidence is accumulating for a role of DKK-1 in PDB. At present there is no cure for PDB and the current treatment of choice are bisphosphonates. These treat the resorptive phase of PDB but do not prevent its return. This article offers a new perspective on the aetiology of PDB and speculate on DKK-1 as a therapeutic target.
Affiliation:
Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry / University of Chester ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry
Citation:
Expert Opinion on Therapeutic Targets, 2010, 14(2), pp. 221-230
Publisher:
Ashley
Journal:
Expert Opinion on Therapeutic Targets
Publication Date:
Feb-2010
URI:
http://hdl.handle.net/10034/197704
DOI:
10.1517/14728220903525720
Additional Links:
http://informahealthcare.com/doi/abs/10.1517/14728220903525720; http://informahealthcare.com
Type:
Article
Language:
en
Description:
This article is not available through ChesterRep.
ISSN:
1472-8222; 1744-7631
Appears in Collections:
Biological Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorMcCarthy, Helen S.en
dc.contributor.authorMarshall, Michael J.en
dc.date.accessioned2011-12-16T17:10:51Zen
dc.date.available2011-12-16T17:10:51Zen
dc.date.issued2010-02en
dc.identifier.citationExpert Opinion on Therapeutic Targets, 2010, 14(2), pp. 221-230en
dc.identifier.issn1472-8222en
dc.identifier.issn1744-7631en
dc.identifier.doi10.1517/14728220903525720en
dc.identifier.urihttp://hdl.handle.net/10034/197704en
dc.descriptionThis article is not available through ChesterRep.en
dc.description.abstractThis article discusses Dickkopf-1 (DKK-1), which is a soluble inhibitor of Wnt signalling and its excessive expression contributes to bone loss in rheumatoid arthritis and multiple myeloma. New therapeutics have been developed for treatment of these conditions that target DKK-1 expression. DKK-1 is elevated in serum of patients with Paget's disease of the bone (PDB) and evidence is accumulating for a role of DKK-1 in PDB. At present there is no cure for PDB and the current treatment of choice are bisphosphonates. These treat the resorptive phase of PDB but do not prevent its return. This article offers a new perspective on the aetiology of PDB and speculate on DKK-1 as a therapeutic target.en
dc.language.isoenen
dc.publisherAshleyen
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1517/14728220903525720en
dc.relation.urlhttp://informahealthcare.comen
dc.subjectdickkopf-1en
dc.subjectosteoprotegerin (OPG)en
dc.subjectosteoblasten
dc.subjectosteoclasten
dc.subjectPaget's disease of boneen
dc.subjectreceptor activator of nuclear factor kappa beta (RANK)en
dc.subjectwnt signallingen
dc.subjectreceptor activator of nuclear factor kappa beta ligand (RANKL)en
dc.titleDickkopf-1 as a potential therapeutic target in Paget's disease of boneen
dc.typeArticleen
dc.contributor.departmentCharles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestry / University of Chester ; Charles Salt Centre, Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Trust in Oswestryen
dc.identifier.journalExpert Opinion on Therapeutic Targetsen
This item is licensed under a Creative Commons License
Creative Commons
All Items in ChesterRep are protected by copyright, with all rights reserved, unless otherwise indicated.